Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Restenosis after angioplasty of arteriovenous fistula (AVF) and central venous stenosis is mainly driven by neointimal hyperplasia (NIH). Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), approved for anemia in chronic kidney disease, may influence vascular remodeling and angiogenesis, but their effect on post-angioplasty outcomes remains unclear. This study evaluated safety, patency, and intima–media thickness (IMT) progression when HIF-PHI was initiated after angioplasty
This single-center prospective observational cohort included hemodialysis patients undergoing angioplasty for dysfunctional AVF or central venous stenosis between december 2024 and August 2025. HIF-PHI was initiated within seven days post-procedure. Patients were followed at one and three months with hemoglobin, access flow, IMT by Doppler ultrasound, and clinical outcomes. Primary endpoints were target lesion primary patency (TLPP) and circuit primary patency (CPP) at three and six months. Secondary endpoints included hemoglobin response, access flow, IMT progression, re-intervention rate, and complications. Kaplan–Meier analysis was used for TLPP.
Thirty-four patients were enrolled (mean age 54.0 ± 11.2 years; 52.9% male; 47.1% diabetes; 82.3% hypertension). Technical success was 100%. Mean balloon diameter was 8.5 ± 3.6 mm and maximal inflation pressure 27.6 ± 3.8 atm; no stents were deployed. Hemoglobin increased from 8.9 ± 1.2 g/dL at baseline to 10.1 ± 1.3 at one month (p < 0.01) and 11.2 ± 1.4 at three months (p < 0.001). Access flow improved from 650 ± 280 to 1695 ± 350 mL/min (p < 0.001). CPP was 100% at three months and 97.1% at six months; TLPP was 97.1% and 94.1%, respectively. Two patients (5.9%) required re-intervention within six months. Kaplan–Meier TLPP was 100% at 90 and 180 days (two censored cases). No access thrombosis or systemic thromboembolism occurred. IMT increased modestly from 0.42 ± 0.07 mm post-procedure to 0.45 ± 0.09 mm at one month (p = 0.12) and 0.51 ± 0.11 mm at three months (p = 0.04).
Parameter
Value (Mean ± SD or n, %)
p-value*
Patient characteristics
Age (years)
54.0 ± 11.2
–
Male sex
18 (52.9%)
Diabetes mellitus
16 (47.1%)
Hypertension
28 (82.3%)
Procedural outcomes
Technical success
34 (100%)
Balloon diameter (mm)
8.5 ± 3.6
Max inflation pressure (atm)
27.6 ± 3.8
Stent deployment
0 (0.0%)
Hematologic response
Hemoglobin baseline (g/dL)
8.9 ± 1.2
Hemoglobin at 1 month
10.1 ± 1.3
<0.01 vs baseline
Hemoglobin at 3 months
11.2 ± 1.4
<0.001 vs baseline
Access function
Access flow baseline (mL/min)
650 ± 280
Access flow post-procedure
1695 ± 350
Flow change (Δ, mL/min)
+1045
Patency outcomes
Circuit patency at 3 months
34/34 (100%)
Circuit patency at 6 months
33/34 (97.1%)
Target lesion patency at 3 months
Target lesion patency at 6 months
32/34 (94.1%)
Re-interventions ≤ 6 months
2/34 (5.9%)
Safety
Access thrombosis
0/34 (0%)
Systemic thromboembolism
0/34
Other complications
None reported
IMT progression
IMT post-procedure (mm)
0.42 ± 0.07
IMT at 1 month (mm)
0.45 ± 0.09
0.12 vs baseline
IMT at 3 months (mm)
0.51 ± 0.11
0.04 vs baseline
HIF-PHI initiation after angioplasty was safe, improved anemia and access flow, and maintained excellent short-term patency. IMT progression was mild, supporting feasibility and warranting larger controlled trials.
